行情

CRIS

CRIS

居里
NASDAQ

实时行情|Nasdaq Last Sale

0.6699
-0.0340
-4.83%
已收盘, 16:00 04/01 EDT
开盘
0.7200
昨收
0.7039
最高
0.7200
最低
0.6600
成交量
15.57万
成交额
--
52周最高
2.900
52周最低
0.6460
市值
2,450.65万
市盈率(TTM)
-0.6915
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测CRIS价格均价为9.00,最高价位9.00,最低价为9.00。

EPS

CRIS 新闻

更多
  • Edited Transcript of CRIS earnings conference call or presentation 19-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 6天前
  • Curis reports Q4 results
  • seekingalpha · 03/20 01:04
  • Curis Inc.'s (CRIS) CEO James Dentzer on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 03/19 23:33
  • Curis Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update
  • PR Newswire · 03/19 21:01

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

CRIS 简况

Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
展开

微牛提供Curis, Inc.(NASDAQ-CRIS)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的CRIS股票新闻,以帮助您做出投资决策。